Vasopressin

Emergency Medicine

Volumn 14, Issue 3, 2002, Pages 304-314

  Barlow, Mark ^a  

^a WELLINGTON HOSPITAL   (New Zealand)

Author keywords

Advanced cardiac life support; Heart arrest; Septic shock; Vasoconstrictor agents; Vasopressins

Indexed keywords

ACETYLCHOLINE; ADRENALIN; ANGIOTENSIN; DOPAMINE; HISTAMINE; NICOTINE; NORADRENALIN; PROSTAGLANDIN DERIVATIVE; VASOPRESSIN;

ACIDOSIS; ANTIDIURESIS; DIABETES INSIPIDUS; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; EDITORIAL; EMERGENCY TREATMENT; EMERGENCY WARD; ESOPHAGUS VARICES BLEEDING; HEALTH CARE COST; HEART ARREST; HEMODYNAMIC MONITORING; HISTORY OF MEDICINE; HORMONE ACTION; HUMAN; HYPERCAPNIA; HYPOTENSION; HYPOVOLEMIA; HYPOXIA; PAIN; PRIORITY JOURNAL; SHOCK; VASODILATATION;

EID: 0036739475     PISSN: 10356851     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2026.2002.00349_2.x     Document Type: Editorial

References (101)

1. Holmes CL, Patel BM, Russell JA et al. Physiology of vasopressin relevant to management of septic shock. Chest 2001; 120: 989-1002.
2. Wenzel V, Lindner KH. Employing vasopressin during cardiopulmonary resuscitation and vasodilatory shock as a lifesaving vasopressor. Cardiovasc. Res. 2001; 51: 529-41.
3. Wenzel V, Ewy GA, Lindner KH. Vasopressin and endothelin during cardiopulmonary resuscitation. Crit. Care Med. 2000; 28 (Suppl. N): 233-5.
4. Morley P. Vasopressin or epinephrine: which initial vasopressor for cardiac arrests? (Commentary). Lancet 2001; 358: 85-6.
5. Stiell IG, Hebert PC, Wells GA et al. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial. Lancet 2001; 358: 105-9.
6. Gazmuri RJ, Ayoub IM. Pressors for cardiopulmonary resuscitation. Is there a new kid on the block? (Commentary). Crit. Care Med. 2000; 28: 1236-8.
7. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N. Engl. J. Med. 2001; 345: 588-95.
8. Tsuneyoshi I, Yamada H, Kakihana Y et al. Haemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med. 2001; 29: 487-93.
9. Gazmuri RJ, Shakeri SA. Low-dose vasopressin for reversing vasodilation during septic shock. (Editorial). Crit. Care Med. 2001; 29: 673-5.
10. Babbs CF, Berg RA, Kette F et al. Use of pressors in the treatment of cardiac arrest. Ann. Emerg. Med. 2001; 37 (Suppl.): 152-62.
11. Schleien CL, Osmond MH, Hickey R. Postresuscitation management. Ann. Emerg. Med. 2001; 37 (Suppl.): 182-95.
12. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J. Endocrinol. 1998; 156: 223-9.
13. Mouillac B, Chini B, Balestre MN et al. The binding site of neuropeptide vasopressin V1a receptor: evidence for a major localisation within transmembrane regions. J. Biol. Chem. 1995; 270: 25 771-7.
14. Laszlo FA, Lazlo F Jr, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol. Rev. 1991; 43: 73-108.
15. Oyama H, Suzuki Y, Satoh S et al. Role of nitric oxide in the cerebral vasodilatory responses to vasopressin and oxytocin in dogs. J. Cereb. Blood Flow Metab. 1993; 13: 285-90.
16. Vanhoutte PM, Katusic ZS, Shepherd JT. Vasopressin induces endothelium-dependent relaxations of cerebral and coronary, but not of systemic arteries. J. Hypertension 1984; 2 (Suppl.): 421-2.
17. Undesser KP, Hasser EM, Haywood JR et al. Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits. Circ. Res. 1985; 56: 410-17.
18. Luk J, Ajaelo I, Wong V et al. Role of V1 receptors in the action of vasopressin on the baroreflex control of heart rate. Am. J. Physiol. 1993; 265: 524-9.
19. Cowley AW Jr, Monos E, Guyton AC. Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ. Res. 1974; 34: 505-14.
20. Noguera I, Medina P, Segarra G et al. Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery. Br. J. Pharmacol. 1997; 122: 431-8.
21. Segarra G, Medina P, Domenech C et al. Role of vasopressin in adrenergic neurotransmission in human penile blood vessels. J. Pharmacol. Exp. Ther. 1998; 286: 1315-20.
22. McVicar AJ. Dose-response effects of pressor doses of arginine vasopressin on renal haemodynamics in the rat. J. Physiol. 1988; 404: 535-46.
23. Russ RD, Walker BR. Role of nitric oxide in vasopressinergic pulmonary vasodilation. Am. J. Physiol. 1992; 262: 743-7.
24. Aikawa T, Kasahara T, Uchiyama M. Circadian variation of plasma arginine vasopressin concentration, or arginine vasopressin in enuresis. Scand. J. Urol. Nephrol. 1999; 202 (Suppl.): 47-9.
25. Doris PA. Vasopressin and central integrative processes Neuroendocrinology 1984; 38: 75-85.
26. Irmscher K, Sennejunker K, Wiegelmann W et al. Therapy of diabetes insipidus with 1-deamino-8-D-arginine-vasopressin. Deutsch Med. Wschr. 1974; 99: 2431-7.
27. Kosman M. Evolution of a new antidiuretic agent, desmopressin acetate (DDAVP).JAMA 1978; 240: 1896-7.
28. Soderlund C. Vasopressin and g]ypressin in upper gastrointestinal bleeding. Scand. J. Gastroenterol. 1987; 22 (Suppl. 137): 50-5.
29. Stump DL, Hardin TC. The use of vasopressin in the treatment of upper gastrointestinal haemorrhage. Drugs 1990; 39: 38-53.
30. Rice TL. Treatment of esophageal varices. Clin. Pharm. 1989; 8: 122-31.
31. Doemeny J, Baum S. Vasopressin infusion for the treatment of esophageal haemorrhage. Semin. Intervent. Radiol. 1988; 5: 73-5.
32. Kravetz D, Bosch J, Teves J et al. Comparison of intravenous somatostatin and vasopressin infusions in the treatment of acute variceal haemorrhage. Hepatology 1984; 4: 442-6.
33. Jenkins SA, Baxter JN, Corbett W et al. A prospective randomised controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal haemorrhage. Br. Med. J. 1985; 290: 275-8.
34. Basso N, Bagarani M, Quondamcarlo C et al. Effective control of variceal bleeding by somatostatin: a double-blind, randomised, cross-over study. Gastroenterology 1986; 84: 1100.
35. Fogel MR, Knaver M, Andrew LL et al. Continuous intravenous vasopressin in active upper gastrintestinal bleeding. Ann. Intern. Med. 1982; 96: 565-9.
36. Burroughs AK, McCormick PA, Hughes MD et al. Randomised, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Gastroenterology 1990; 99: 1388-95.
37. Grosman I, Simon D. Potential gastrointestinal uses of somatostatin and its synthetic analogue octreotide. Am. J. Gastroenterol. 1990; 85: 1061-72.
38. Shields R, Jenkins SA, Baxter JN et al. A prospective randomised controlled trial comparing the efficacy of somatostatin with injection sclerotherapy in control of bleeding esophageal varices. J. Hepatol. 1992; 16: 128-37.
39. Achauer BM, Hernandez J, Parker A. Burn excision with intraoperative vasopressin. J. Burn Care Rehabil. 1989; 10: 375-8.
40. Pyeritz RE, Droller MJ, Bender WL et al. An approach to the control of massive haemorrhage in cyclophosphamide induced cystitis by intravenous vasopressin: a case report. J. Urol. 1978; 120: 253.
41. Daloze PM, Arnoux R, Carmen J et al. Vasopressin use in human liver transplantation. Transplant Proc. 1987; 19: 2424-6.
42. Lurie S, Appleman Z, Katz Z. Subendometrial vasopressin to control intractable placental bleeding. (Letter). Lancet 1997; 349: 698.
43. Townsend DE, Barbis SD, Matthews RD. Vasopressin and operative hysteroscopy in the management of delayed postabortion and postpartum bleeding. Am. J. Obstet. Gynaecol. 1991; 165: 1405-7.
44. Legros J, Timisit-Berthier M. Vasopressin and vasopresin analogues for treatment of memory disorders in clinical practice. Prog. Neuropsychopharmacol. Biol. Psychiatry 1988; 12: 71-86.
45. Prengel AW, Lindner KH, Ensinger H et al. Plasma catecholamine concentrations after successful resuscitation in patients. Crit. Care Med. 1992; 20: 609-14.
46. Lindner KH, Strohmenger HU, Ensinger H et al. Stress hormone response during and after CPR. Anesthesiology 1992; 77: 662-8.
47. Lindner KH, Haak T, Keller A et al. Release of endogenous vasopressin during and after cardiopulmonary resuscitation. Heart 1996; 75: 145-50.
48. Lindner KH, Brinkmann A, Pfenninger EG et al. Effect of vasopressin on haemodynamic variables, organ blood flow, and acid-base status in a pig model of cardiopulmonary resuscitation. Anesth. Analg. 1993; 77: 427-35.
49. Lindner KH, Prengel AW, Pfenninger EG et al. Vasopressin improves vital organ blood flow during closed-chest cardio-pulmonary resuscitation in pigs. Circulation 1995; 91: 215-21.
50. Lindner KH, Prengel AW, Brinkmann A et al. Vasopressin administration in refractory cardiac arrest. Ann. Intern. Med. 1996; 124: 1061-4.
51. Wenzel V, Lindner KH, Prengel AW et al. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcountershock pulseless activity in pigs. Crit. Care Med. 1999; 27: 486-92.
52. Wenzel V, Lindner KH, Krismer AC et al. Repeated administration of vasopressin, but not epinephrine, maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 1999; 99: 1379-84.
53. Baber SI, Berg RA, Hilwig RW et al. Vasopressin versus epinephrine during cardiopulmonary resuscitation. A randomised swine outcome study. Resuscitation 1999; 41: 185-92.
54. Prengel AW, Lindner KH, Keller A. Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Stroke 1996; 27: 1241-8.
55. Strohmenger HU, Lindner KH, Keller A et al. Effects of graded doses of vasopressin on median fibrillation frequency in a porcine model of cardiopulmonary resuscitation, results of a prospective randomised, controlled trial. Crit. Care Med. 1996; 24: 1360-5.
56. Wenzel V, Lindner KH, Prengel AW et al. Endobronchial vasopressin improves survival during cardiopulmonary resuscitation in pigs. Anesthesiology 1997; 86: 1375-81.
57. Wenzel V, Lindner KH, Augenstein S et al. Intraosseus vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. Crit. Care Med. 1999; 27: 1565-9.
58. Paradis NA, Martin GB, Rivers EP et al. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA 1990; 263: 1106-13.
59. Wenzel V, Lindner KH, Krismer AC et al. Improved survival and neurological outcome with vasopressin after prolonged resuscitation in pigs. J. Am. Coll. Cardiol. 2000; 35: 527-33.
60. Krismer AC, Hogan QH, Wenzel V et al. Cardiac arrest during epidural anaesthesia: a comparison between epinephrine and vasopressin in a porcine CPR model. Circulation 1999; 100 (Suppl. 1): 1636.
61. Krismer AC, Lindner KH, Kornberger R. et al. CPR during severe hypothermia in pigs: does epinephrine or vasopressin increase coronary perfusion pressure? Anesth. Analg. 2000; 90: 69-73.
62. Voelckel WG, Lurie KG, Lindner KH et al. Vasopressin improves survival after cardiac arrest in hypovolaemic shock. Anesth. Analg. 2000; 91: 627-34.
63. Lindner KH, Prengel AW, Brinkmann A et al. Vasopressin administration in refractory cardiac arrest. Ann. Intern. Med. 1996; 124: 1061-4.
64. Morris DC, Dereczyk BE, Grzybowski M et al. Vas opressin can increase coronary perfusion pressure during human cardiopulmonary resuscitation. Acad. Emerg. Med. 1997; 4: 878-83.
65. Lindner KH, Dirks B, Strohmenger HU et al. A randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997; 349: 535-7.
66. European Resuscitation Council Guidelines 2000 for Adult Advanced Life Support. A statement from the Advanced Life Support Working Group and approved by the Executive Committee of the European Resuscitation Council. Resuscitation 2001; 48: 211-21.
67. Wilson RF, Thal AP, Kindling PH et al. Haemodynamic measurements in septic shock. Arch. Surg. 1965; 91: 121-9.
68. Suffredini AF, Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of endotoxin. N. Engl. J. Med. 1989; 321: 280-7.
69. Sylvester JT, Scharf SM, Gilbert RD et al. Hypoxic and CO hypoxia in dogs: haemodynamics, carotid reflexes and catecholamines. Am. J. Physiol. 1979; 236: 22-8.
70. Benedict CR, Rose JA. Arterial norepinephrine changes in patients with septic shock. Circ. Shock 1992; 38: 165-72.
71. Cumming AD, Driedger A, McDonald JWD et al. Vasoactive hormones in the renal response to systemic sepsis. Am. J. Kidney Dis. 1988; 11: 363.
72. Arnauld E, Czernichow P, Fumoux F et al. The effects of hypotension and hypovolaemia on the liberation of vasopressin during haemorrhage in the unanaesthetised monkey (Macaca mulatta). Pflugers Arch. Eur. J. Physiol. 1977; 371: 193-200.
73. Wilson MF, Brackett DJ, Tompkins P et al. Elevated plasma vasopressin concentrations during endotoxin and E. coli shock. Adv. Shock Res. 1981; 6: 15-26.
74. Brackett DJ, Schaefer CF, Wilson MF. The role of vasopressin in the maintenance of cardiovascular function during early endotoxin shock. Adv. Shock Res. 1983; 9: 147-56.
75. Rurak DW. Plasma vasopressin levels during haemorrhage in mature and immature fetal sheep. J. Dev. Physiol. 1979; 1: 91-101.
76. Errington ML, Rocha E, Silva M Jr. Vasopressin clearance and secretion during haemorhage in normal dogs and in dogs with experimental diabetes insipidus. J. Physiol. 1972; 227: 395-418.
77. Zerbe RL, Feurstein G, Kopin IJ. Effect of captopril on cardiovascular, sympathetic and vasopressin responses to haemorrhage. Eur. J. Pharmacol. 1981; 72: 391-5.
78. Morales D, Madigan J, Cullinane S et al. Reversal by vasopressin of intractable hypotension in the late phase of haemorrhagic shock. Circulation 1999; 100: 226-9.
79. Landry DW, Levin HR, Gallant EM et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122-5.
80. Argenziano M, Choudhri AF, Oz MC et al. A prospective randomised trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96 (Suppl. II): 286-90.
81. Cooke CR, Well BM, Jones GV et al. Reversible vasopressin deficiency in severe hypernatraemia. Am. J. Kidney Dis. 1993; 22: 44-52.
82. Negro-Vilar A, Samson WK. Dehydration-induced changes in immunoreactive vasopressin levels in specific hypothalamic structures. Brain Res. 1979; 169: 585-9.
83. Garrard CS, Kontoyannis DA, Piepoli M. Spectral analysis of heart rate variability in the sepsis syndrome. Clin. Auton. Res. 1993; 3: 5-13.
84. Zerbe RL, Henry DP, Robertson GL. Vasopressin response to orthostatic hypotension: etiologic and clinical implications. Am. J. Med. 1983; 74: 265-71.
85. Reid IA. Role of nitric oxide in the regulation of renin and vasopressin secretion. Front Neuroendocrinol. 1994; 15: 351-83.
86. Landry DW, Levin HR, Gallant EM et al. Vasopressin vasopressor hypersensitivity in vasodilatory septic shock. Crit. Care Med. 1997; 25: 1279-82.
87. Kaufmann H, Oribe E, Oliver JA. Plasma endothelin during upright tilt: relevance for orthostatic hypotension? Lancet 1991; 338: 1542-5.
88. Chen JM, Cullinane S, Spanier TB et al. Vasopressin deficiency and pressor hypersensitivity in haemodynamically unstable organ donors. Circulation 1999; 100: (Suppl. II) 244-6.
89. Wagner HN Jr, Braunwald E. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J. Clin. Invest 1956; 35: 1412-18.
90. Padfield PL, Brown JJ, Lever AF et al. Changes of vasopressin in hypotension: cause or effect? Lancet 1976; 1: 1255-7.
91. Idem. Blood pressure in acute and chronic vasopressin excess. studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. N. Engl. J. Med. 1981; 1304: 1067-70.
92. Thiemermann C, Szabo C, Mitchell JA et al. Vascular hyporeactivity to vasoconstrictor agents and haemodynamic decompensation in haemorrhagic shock is mediated by nitric oxide. Proc. Natl Acad. Sci. USA 1973; 90: 267-71.
93. Middleton S. The effects of renin and angiotonin during haemorrhagic hypotension and shock. Am. J. Physiol. 1944; 141: 132-7.
94. Hollenberg SM, Piotrowski MJ, Parrillo JE. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to endothelin-1 in septic rats. Am. J. Physiol. 1997; 272: 969-74.
95. Schwartz J, Reid IA. Role of vasopressin in blood pressure regulation in conscious water-deprived dogs. Am. J. Physiol. 1983; 244: 74-7.
96. Bartelstone HJ, Nasmyth PA. Vasopressin potentation of catecholamine actions in dog, rat, cat and rat aortic strip. Am. J. Physiol. 1965; 208: 754-62.
97. Wakatsuki T, Nakaya Y, Inoue I. Vasopressin mediates K-channel activities of cultured smooth muscle cells from porcine coronary artery. J. Physiol. 1992; 263: 491-6.
98. Umino T, Kusano E, Muto S et al. AVP inhibits LPS- and IL-IB-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells. Am. J. Physiol. 1999; 276: 433-41.
99. Nambi P, Whitman M, Gessner G et al. Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle line. Proc. Natl Acad. Sci. USA 1986; 83: 8492-5.
100. Rozenfeld V, Cheng JW. The role of vasopressin in the treatment of vasodilation in shock states. Ann. Pharmacother. 2000; 34: 250-4.
101. Malay MB, Ashton RC Jr, Landry DW et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J. Trauma 1999; 47: 699-703.